Leaflet Thrombosis

WASHINGTON — In the ADAPT-TAVR trial of patients who had transcatheter aortic valve replacement and no indication for long-term anticoagulation, edoxaban did not improve leaflet thrombosis compared with dual antiplatelet therapy.

Low-risk patients who underwent transcatheter aortic valve replacement and took oral anticoagulation for 30 days had lower incidence of leaflet thrombosis without increased bleeding compared with those who took aspirin after the procedure, according to data from the Low-Risk TAVR trial presented at Cardiovascular Research Technologies.

Healio was on-site at TCT 2019, which offered a number of late-breaking presentations on innovations in the treatment of structural heart disease. Below are some of the highlights.